new drug development, 41

recommendations for research, 5, 87

relapse behavior, 69

Antiaddiction medications, 27, 29.

See also Pharmacotherapy

Antisocial personality, 123, 181

Anxiety disorders, 211

Arachidonic acid, 59

Assessment instruments, 201-202, 239

B

Barbiturates, 66

Behavioral research

in abuse liability research, 38-39

on aggression and violence, 47-48

behavioral models, 36-37

contributions of, 3-4, 35

craving response, 46-47

economic modeling, 49-50

future prospects, 50-51

learning and conditioning in treatment models, 41-42

on motivation for drug use, 43-45

neuroscience research and, 37-38

for pharmacotherapies, 39-41, 203

recommendations for, 4, 51

risk factors for drug use, 48-49

on withdrawal, 42

Benzodiazepines, 211

antagonists, 70

Biomarkers, 121, 173-174

Bromocriptine, 71

Buprenorphine, 195-196

C

Ca2+ neurotransmitter pathway, 59, 60

Cannabis. See Marijuana

Cerebral blood flow measurement, 73

Children/adolescents

antismoking campaigns, 145-146

community-based preventive interventions, 146

confidentiality issues in treatment, 270

consequences of prenatal drug exposure, 170-171, 174-175

developmental risks in drug use, 8, 166-167

epidemiological surveys, 99-101, 106

parental drug abuse, 175

peer risk factors, 125-126

predictors of adult substance abuse, 122-123

preventive intervention design, 140

racial differences in drug use, 128

risk factors, 128-129

school-based prevention programs, 141-143, 147-149, 152

treatment considerations, 214-215

Clonidine, 68, 70, 71

Clorazepate, 211

Cocaine

aggressive behavior and, 47

antiaddiction medications, 203

brain glucose metabolism in use of, 73

craving response in users, 46-47

day hospital vs. inpatient treatment, 240-241

dopaminergic effects, 37, 64, 73, 82

drug interactions, 173

effects on male reproduction, 174

extent of abuse, 2, 21, 193

extent of dependence, 102

immunization, 39-40, 85

market characteristics, 260

maternal use during pregnancy, 166, 167

neurochemical response, 61, 64, 68

pharmacological antagonists, 70

prenatal exposure, 171-172

treatment vs. drug control/interdiction, 199-200

violence linkage, 178-179

withdrawal, 67, 68

See also Crack cocaine

Cognitive-behavioral psychology, 42, 196

Community Epidemiology Work Group, 105



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement